Study of Thermo-Sensitive In-Situ Gels for Ocular Delivery by Bhowmik, Manas et al.
Sci  Pharm   www.scipharm.at 
Research article  Open Access 
Study of Thermo-Sensitive  
In-Situ Gels for Ocular Delivery 
Manas BHOWMIK * 
1, Sanchita DAS 
1,  
Dipankar CHATTOPADHYAY 
2, Lakshmi K. GHOSH 
1 
1 Pharmaceutics Research Lab II, Department of Pharmaceutical Technology, Jadavpur University, Kolkata-
700 032, India.  
2 Department of Polymer Science & Technology, University College of Science & Technology, 92, A.P.C. 
Road, University of Calcutta, Kolkata-700 009, India. 
* Corresponding author. E-mail: b_manasju@yahoo.co.in (M. Bhowmik) 
Sci Pharm. 2011; 79: 351–358        doi:10.3797/scipharm.1010-04 
Published:   March 5
th  2011     Received:    October  14
th 2010 
Accepted:   March 1
st 2011 
This article is available from: http://dx.doi.org/10.3797/scipharm.1010-04 
© Bhowmik et al.; licensee Österreichische Apotheker-Verlagsgesellschaft m. b. H., Vienna, Austria. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License 
(http://creativecommons.org/licenses/by/3.0/), which permits unrestricted use, distribution, and reproduction 
in any medium, provided the original work is properly cited. 
Abstract 
The aim of the present study was the development of thermo-sensitive in-situ 
gels for in-vitro evaluation of ophthalmic delivery systems of ketorolac 
tromethamine (KT), based on methylcellulose (MC) in combination with 
hydroxypropylmethyl cellulose (HPMC). The gel temperature of 1% MC solution 
was observed at 60°C. It was found that 6% oral rehydration salt without 
dextrose (ORS) was capable to reduce the gel temperature below physiological 
temperature. HPMC was added to increase viscosity and drug release time. 
The results indicated a large increase in viscosity at 37°C with addition of 
HPMC whch provided sustained release of the drug over a 4h period. From 
in-vitro release studies, it could be concluded that the developed systems were 
thus a better alternative to conventional eye drops. 
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Introduction 
The conventional liquid ophthalmic formulations are washed out from the precorneal area 
immediately upon instillation because of constant lacrimal secretion, nasolacrimal drainage 
and short precorneal residence time of the solution [1]. As a result, frequent instillation of 
solution or higher drug concentration is needed to achieve the desired therapeutic 352 M.  Bhowmik  et al.:  
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response [2, 3]. But this attempt is potentially dangerous if drug solution drained from the 
eye is systemically absorbed from the nasolacrimal duct [4]. To increase precorneal 
residence time and ocular bioavailability, different ophthalmic delivery systems such as 
viscous solutions, ointments, gels, suspensions or polymeric inserts are used [5]. But 
because of blurred vision (e.g. ointments) or lack of patient compliance (e.g. inserts), these 
formulations have not been widely accepted. This problem can be overcome by using in-
situ gel forming ocular drug delivery system, prepared from polymer, exhibit sol-to-gel 
phase transition due to a change in a specific physico-chemical parameter (pH, temper-
ature, etc.) in their environment [6] and as a result sustained drug release to the eye 
occurs [7]. Such formulations where used to delivered bioactive agents by instillation into 
the eye, which upon exposure to the eye temperature changes to the gel phase [8]. Thus 
precorneal residence time of the delivery system is increased and ocular bioavailability is 
also enhanced. MC solution is known to undergo thermoreversible sol-to-gel transition. Gel 
temperature of MC can be reduced by adding salts and other additives [9]. 
The objective of the research work was to formulate thermo-sensitive in-situ gel ocular 
delivery systems. The model drug used was ketorolac tromethamine, to treat seasonal 
allergies such as itching, swelling and inflammation of the eyes.  
Results and Discussion 
In-vitro gelation studies 
The gel temperature of 1% MC solution is 60°C. The effect of ORS on gel temperature of 
MC solution has been shown in figure 1. The gel temperature is reduced below body 
temperature by addition of ORS. The addition of salt will affect the structure of water, 
which is mainly due to the interactions between ions and water molecules. Salting out salts 
of ORS stronger interact with water than hydrogen bonds between water molecules. As a 
result the hydrogen bonds between water molecules are destroyed by the salt [10]. Salt 
ions also attract more water molecules due to their stronger hydration abilities than MC 
chains. This effect decreases water-solubility of MC. In this situation formation of 
hydrophobic aggregates are more pronounced in a salt containing MC solution. The 
increased salt content results in fewer free water molecules around MC chains and a 
stronger hydrophobic environment for MC. So the sol-gel transition occurs at a lower 
temperature. It has been observed that 6% ORS is capable to ensure a gelation 
temperature below body temperature and the solutions are free flowing liquid to allow 
reproducible instillation into the eye as drops at room temperature. HPMC does not 
significantly alter the gel temperature. All the developed formulations were evaluated for 
clarity by visual inspection and clarity was sufficient.  
Viscosity study 
The viscosity of the formulations is investigated as a function of temperature. The 
formulations behave as liquids and exhibit low viscosity at 25°C. At 37°C, the solutions are 
converted into gels with high viscosity. The reasons for this increase in viscosity are that 
the polymers are fully hydrated and simple entanglement exists between polymer chains at 
low temperature. The hydration of polymer by water is gradually weakened when the 
temperature increases, the hydrophobic association of polymer becomes more 
pronounced and a gel structure is formed. It has been observed that the viscosity 
enhancing capability of HPMC is much higher than MC alone as shown in table 1.    Study of Thermo-Sensitive In-Situ Gels for Ocular Delivery  353 
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Fig. 1.  Variation in gelation temperature of 1% MC solution with increasing 
concentration of ORS (mean ± S.D., n=3). 
Swelling study 
The in-situ gels were observed to be stable throughout the period of swelling (7 hr.). The 
rate of swelling of F2 was slower than that of F1 (Table 1). This is due to the higher 
viscosity of F2 at 37°C which decreases water penetration. The results show that HPMC 
containing in-situ gels are less swollen than MC gel because of formation of highly stiff 
gels of HPMC in combination with MC. 
Tab. 1.  Characteristics and in-vitro drug release kinetics of in-situ gel systems (n=3). 
Formu- 
lation 
Composition 
(1% Polymer 
solution + 
0.5% KT + 6% 
ORS) 
Viscosity 
at 20 rpm 
and 37°C 
(cP± S.D.) 
Swelling at 
3 hrs.  
(K± S.D.) 
Hydration 
Rate of 
Each Drop 
(0.05 ml) of 
in-situ Gel 
(μl/min) 
Leached ion 
Concentration  
(mmol min
−1 
drop
−1 × 10
−4) 
  MC:HPMC      Na
+ K
+ 
F1 1:0  15100.00 ± 
6.24 
0.04 ± 0.00 0.0097 ± 
0.0008 
2.17 ± 0.06  0.30 ± 0.02
F2 2:1  17200.00 ± 
4.73 
0.03 ± 0.00 0.0119 ± 
0.0001 
1.58 ± 0.08  0.17 ± 0.01
  Zero-order First-order Higuchi  Korsmeyer-Peppas   
  r
2 ± S. D.  r
2 ± S. D.  r
2 ± S. D.  r
2 ± S. D.  n   
F1 0.9791  ± 
0.0012 
0.9877 ± 
0.0009 
0.9903 ± 
0.0012 
0.9965 ± 
0.0009 
0.51 ± 0.01   
F2 0.9708  ± 
0.0004 
0.9818 ± 
0.0073 
0.9884 ± 
0.0011 
0.9963 ± 
0.0039 
0.78 ± 0.06   
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In-vitro drug release studies and release kinetics 
According to the in-vitro drug release profiles of in-situ gels (figure 2), the drug loading is 
nearly fully released within 1.5 hrs from MC solution. At 37°C, the in-situ gel matrix is 
formed in which water penetration and hydration is the rate limiting step of drug release. It 
has been observed that addition of ORS (mixture of 3.5g NaCl, 1.5g KCl and 2.5g 
NaHCO3) will increase the drug release time up to 3hrs. This is due to an increase in 
viscosity of in-situ MC gel solution in presence of ORS at 37°C. This leads to slower 
solvent penetration and consequently the drug release time will be increased. It is also 
observed that the drug release time increases up to 4 hours with the addition of HPMC in 
MC solution at MC/HPMC ratio 2:1, and this increase in drug delivery time is due to 
increase in viscosity of MC/HPMC combination.  
Zero-order, First-order and Higuchi’s equation were employed to interpret the drug release 
patterns of in-situ-gels. It was found that the in-vitro drug release pattern is best explained 
by Higuchi’s equation, as the plots show the highest linearity (r
2 > 0.9884±0.0011) followed 
by first order and zero order equation (Table 1). The results show that viscosity of F2 is 
higher than F1 and increased viscosity causes slower drug release. It has been observed 
that the drug release rate is decreased by addition of HPMC. All the kinetic data were 
analyzed by the Korsmeyer-Peppas Equation (Mt/M¥=kt
n). An acceptable linearity (r
2 >  
0.9963±0.0039) was observed and the release exponent ‘n’ varied from 0.51±0.01 to 
0.78±0.06, which indicated a non-Fickian drug diffusion i. e., coupled diffusion and erosion 
mechanisms. 
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Fig. 2.   Effects of polymers and ORS on in-vitro drug release from MC-Ketorolac 
solution and in-situ gel (mean ± S.D., n=3). 
 
In-vitro compatibility studies 
In human the average tear volume is 6.5–10.7µl/minute and the tear flow is 0.5–2.2 
µl/minute [11]. The hydration rate of the in-situ gels as depicted in table 1 is lower than the 
normal tear flow rate. NaCl, KCl and NaHCO3 show iso-osmolarity to the body fluid at 154   Study of Thermo-Sensitive In-Situ Gels for Ocular Delivery  355 
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mmol, 160 mmol and 175 mmol respectively [9]. According to the results in table 1 the 
amounts of leaked salts are negligible. In addition, 0.5–2% (85.5–342 mmol) NaCl is 
tolerable to normal eye [12]. The results show that the developed in-situ gels are 
compatible to the eye and there are no problems to expect due to irritation of eye caused 
by excessive dehydration of aqueous ocular cavity. 
Stability study 
The stability study was carried out on the formulation at 30 ± 2°C and 60 ± 5% RH over the 
period of 90 days. The formulations retained clarity and no remarkable changes were 
observed in gelation temperature, viscosity, in-vitro drug release profile and salt leaching 
properties as shown in table 2.  
Tab. 2.  Stability profiles of F2 in-situ gel (n=3) 
Leached ion 
Concentration  
(mmol min
−1drop
−1×10
−4)
Time  
interval  
(Days) 
Gel temper- 
ature (°C) 
(mean ± S. 
D.) 
Viscosity (cP) at 
20 rpm and 37°C 
(mean ± S. D.) 
Cumulative  
% drug release 
at 4h  
(mean ± S. D.) Na
+ K
+ 
0 31.03±0.25  17200±4.75  96.76±0.37 1.58±0.08  0.17±0.00 
30 31.10±0.20 17205±6.51  97.75±0.73 1.54±0.06  0.18±0.01 
60 31.17±0.32 17202±6.81  96.20±0.32 1.53±0.04  0.16±0.01 
90 31.13±0.45 17207±9.61  97.23±0.91 1.55±0.05  0.18±0.00 
 
Experimental 
Materials 
Metolose SM 4000 (Methylcellulose, 29.6% methoxyl content) was obtained from Shinetsu 
Chemical Co. Ltd., Japan. Hydroxypropylmethylcellulose (HPMC K15 M) from Colorcon 
Asia Pvt. Ltd., Verna, Goa, India and Ketorolac tromethamine from Sun Pharma, Baroda, 
Gujrat, India were gift samples. The dialysis membrane (LA390, average flat width-25.27 
mm, average diameter-15.9 mm and capacity approx-1.99 ml/cm) was purchased from 
HiMedia Laboratories Pvt. Ltd., Mumbai, India. Sodium chloride (NaCl), Potassium 
chloride (KCl), Calcium chloride (CaCl2) and Sodium bicarbonate (NaHCO3) were 
purchased from E. Merck India Pvt. Ltd., Mumbai, India. All other chemicals were 
analytical grade. 
Preparation of sample solutions 
The methylcellulose (MC, 1%) was dispersed in hot deionised water of 70°C and then 
cooled down below 20°C under continuous stirring until a homogenous dispersion was 
obtained [13]. The dispersion was kept in a refrigerator for 48 hours to get clear solution. 
Oral rehydration salt without dextrose (ORS: mixture of 3.5g NaCl, 1.5g KCl and 2.5g 
NaHCO3) was dissolved in the MC solution and evaluated for gel temperature in order to 
identify the compositions suitable for in-situ gel systems. Ketorolac was then added to the 
in-situ gel systems and the effect of KT on gel temperature was evaluated. The HPMC 
solution (1%) was prepared by same procedure like the MC solution. The required amount 356 M.  Bhowmik  et al.:  
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of MC and HPMC solutions were mixed homogeneously to prepare MC-HPMC solutions at 
a ratio of 2:1 and its in-situ gel solution was also prepared by adding ORS and KT. 
In-vitro gelation studies 
The gelation studies were carried out with a cell, equipped with a thermo jacket for 
maintaining constant temperature. The cell was a cylindrical reservoir capable of holding 
3 ml of gelation solution. This gelation solution was artificial tear fluid (composition: 0.67g 
NaCl, 0.20g NaHCO3, 0.008g CaCl2.2H2O and distilled water qs to 100g) [14]. The 
reservoir was filled with 2 ml of the gelation solution. A 250μl transparent plastic cup 
present in the bottom of the cell to hold the gel sample in place, after its formation. 100 µl 
of the formulated solution was injected into the cavity of the cup, with a thermal cycle of 
20°C to 70°C. The gel temperature was recorded by visual inspection repeatedly [15]. The 
temperature was verified with test tube tilting method by observing the non flowing state of 
the solution [6]. 
Rheological studies 
The rheological studies were conducted in a viscometer (TV-10 Viscometer, Toki Sangyo 
Co. Ltd., Japan). The viscosity of the formulated solutions was measured at a shear rate of 
20 rpm at 37°C. The temperature was maintained by a thermally controlled water bath. 
The samples were equilibrated for 10 minutes to reach the running temperature prior to 
each measurement.  
Swelling study 
The studies were conducted with a cell, equipped with thermo jacket to maintain constant 
temperature. The cell containing artificial tear fluid was used as swelling medium 
equilibrated at 37°C. The 1 ml of formulated solution was packed in a dialysis bag and put 
into the swelling medium. At specific time intervals the bag was removed from the medium 
and weight was recorded. The swelling of the polymer gel as a function of time was 
determined by using the following relationship [16]: % St = (Wt–W0)×100/W0, where St is 
swelling at time‘t’, W0 is the initial weight of the gelling solution and Wt is the final weight of 
the gel. 
In-vitro drug release studies and release kinetics 
The release of ketorolac tromethamine from in-situ gels was determined by using a Franz 
diffusion cell. The dissolution medium was artificial tear fluid (ATF). The dialysis 
membrane, previously soaked overnight in the dissolution medium, was mounted on one 
end of the donor cylinder of the Franz diffusion cell. The acceptor compartment cylinder 
was filled with 40 ml of dissolution medium of 37°C so that the membrane just touched the 
medium surface and the stirring rate was maintained at 50 rpm. One milliliter of the 
formulation was placed over the dialysis membrane. Aliquots, of 1 ml each were withdrawn 
at hourly intervals and replaced by an equal volume of fresh medium. The ketorolac 
tromethamine content of the aliquots was determined by UV spectrophotometry at 323nm.  
In-vitro compatibility studies 
The studies were comprised assessment of gel hydration and salt leaching properties of 
in-situ gel. As generally one or two drops of solution are instilled into the eye, the hydration 
rate of formulations was calculated according to the following equation: Hydration rate   Study of Thermo-Sensitive In-Situ Gels for Ocular Delivery  357 
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[µl/minute] = (9.9122 × Wgs × St × 0.05)/tm. Where Wgs is the weight of 1 ml of gel solution 
[gm], St is the swelling percentage at time t, tm is the swelling time [min] and 100 gm ATF 
was approximately 99.122 ml in volume. The hydration rate of the formulations derives 
from the above equation was compared with the average tear flow rate of humans. The 
salt leaching properties of the formulation were performed similar to the methods for in-
vitro drug release studies. The aliquots were subjected to examine by Easy Lyte Na/K 
Analyzer (Medica, USA).  
Stability study 
The formulation F2 showing optimum gelation, viscosity and drug release was selected for 
the stability study which was conducted according to the International Conference on 
Harmonization guidelines, 2003. A sufficient quantity of gel solution in glass vials was 
stored in desiccator’s containing saturated solution of sodium chloride to maintain an 
approximate relative humidity of 60 ± 5%. The desiccator was kept at room temperature 
(30 ± 2°C) and samples were withdrawn at 0, 30, 60, 90 days. The physical stability of the 
gel was inspected periodically by checking clarity, gel temperature, viscosity, in-vitro drug 
release profile and salt leaching properties. 
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